Tu1848 EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS THROUGH 2 YEARS: RESULTS OF THE UNIFI MAINTENANCE STUDY AND LONGTERM EXTENSION
William J. Sandborn(University of San Diego), Silvio Danese(IRCCS Ospedale San Raffaele), Yiying Zhou(Janssen (United States)), Tadakazu Hisamatsu(Kyorin University), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Colleen Marano(Johnson & Johnson (United States)), Christoph D. O'Brien, Hongyan Zhang(Lanzhou University), Remo Panaccione(University of Calgary), Jewel Johanns(Johnson & Johnson (United States)), Bruce E. Sands(Icahn School of Medicine at Mount Sinai)
Cited by 2
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k